한글목차

세계의 전립선암 진단 시장은 2024년에 89억 2,000만 달러로 평가되며, 2030년까지 CAGR 9.25%로 성장하며, 151억 7,000만 달러에 달할 것으로 예측됩니다. 전립선암 진단은 전립선특이항원(PSA) 혈액검사, 직장수지검사, 각종 영상 진단법, 생검법 등 전립선암의 발견, 특성평가, 병기분류에 사용되는 일련의 의료행위와 검사를 포함합니다. 시장 확대는 주로 전 세계 고령화, 전립선암 발생률 및 유병률 증가, 대중의 인식 개선 및 검진 강화, 진단 방법의 지속적인 기술 발전 등에 의해 주도되고 있습니다.

주요 시장 성장 촉진요인

세계 전립선암 발생률 증가는 의료 시스템이 증가하는 질병 부담에 대처하는 과정에서 진단 시장을 크게 견인하고 있습니다. 이러한 증가 추세로 인해 보다 빈번하고 첨단 스크리닝, 조기 발견 방법, 지속적인 모니터링 전략이 요구되고 있습니다.

주요 시장 과제

세계 전립선암 진단 시장 확대에 있으며, 가장 큰 장벽은 첨단 진단 기술에 따른 막대한 비용입니다. 이러한 고비용은 특히 의료 인프라가 아직 개발 중이고, 예산이 제한적이며, 전문적 시술에 대한 상환제도가 불충분한 지역에서는 의료 시스템과 환자 개개인에게 큰 재정적 부담을 주고 있습니다.

주요 시장 동향

세계 전립선암 진단 시장은 외래 진료 및 재택 진료 환경으로의 진단 서비스 분산화로 인해 큰 영향을 받고 있습니다. 이러한 추세는 기존의 병원 중심 모델에서 보다 접근하기 쉽고 편리한 진단 옵션으로 이동하는 의료 제공의 근본적인 변화를 나타냅니다.

목차

제1장 개요

제2장 조사 방법

제3장 개요

제4장 고객의 소리

제5장 세계의 전립선암 진단 시장 전망

• 시장 규모·예측
  • 금액별
• 시장 점유율·예측
  • 검사 유형별(예비 검사, 확정 검사)
  • 유형별(선암, 간질세포암, 기타)
  • 용도별(병원·진료소, 외래 진료 센터, 기타)
  • 지역별
  • 기업별(2024)
• 시장 맵

제6장 북미의 전립선암 진단 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 전립선암 진단 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 유럽 : 국가별 분석
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 전립선암 진단 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 중동 및 아프리카의 전립선암 진단 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트
  • 남아프리카공화국

제10장 남미의 전립선암 진단 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 남미 : 국가별 분석
  • 브라질
  • 콜롬비아
  • 아르헨티나

제11장 시장 역학

• 촉진요인
• 과제

제12장 시장 동향과 발전

• 합병·인수
• 제품 출시
• 최근 동향

제13장 세계의 전립선암 진단 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• MDx Health, Inc.
• Myriad Genetics, Inc.
• Abbott Laboratories, Inc.
• F. Hoffman-La Roche Ltd.
• Siemens Healthcare AG
• OPKO Health, Inc.
• Exact Sciences Corporation
• Regeneron Pharmaceuticals Inc.

제16장 전략적 제안

제17장 조사회사 소개·면책사항

영문목차

The Global Prostate Cancer Diagnostics Market, valued at USD 8.92 Billion in 2024, is projected to experience a CAGR of 9.25% to reach USD 15.17 Billion by 2030. Prostate cancer diagnostics encompass a suite of medical procedures and tests employed for the detection, characterization, and staging of prostate cancer, including prostate-specific antigen blood tests, digital rectal examinations, various imaging modalities, and biopsy procedures. The market's expansion is primarily propelled by an aging global demographic, the increasing incidence and prevalence of prostate cancer, growing public awareness coupled with enhanced screening initiatives, and continuous technological advancements in diagnostic methodologies.

Key Market Drivers

The increasing global incidence of prostate cancer significantly propels the diagnostics market, as healthcare systems contend with a growing disease burden. This rising prevalence necessitates more frequent and advanced screening, early detection methods, and ongoing monitoring strategies. According to the American Cancer Society, in its January 2024 "Cancer Statistics, 2024" report, nearly 300,000 new cases of prostate cancer were expected in the United States during the year, highlighting the persistent diagnostic demand.

Key Market Challenges

A significant impediment to the expansion of the Global Prostate Cancer Diagnostics Market is the considerable cost associated with advanced diagnostic technologies. These high costs place a substantial financial burden on healthcare systems and individual patients, particularly in regions with developing healthcare infrastructures where budgets are often constrained and reimbursement mechanisms may be insufficient for specialized procedures. This economic barrier directly impacts the ability of healthcare providers to procure and deploy necessary diagnostic equipment and expertise, thus limiting the availability of comprehensive diagnostic services.

Key Market Trends

The Global Prostate Cancer Diagnostics Market is significantly influenced by the decentralization of diagnostic services to outpatient and home settings. This trend represents a fundamental shift in healthcare delivery, moving away from traditional hospital-centric models towards more accessible and convenient diagnostic options. The adoption of at-home collection methods for prostate cancer screening is gaining traction, driven by advancements in non-invasive testing. For instance, in February 2025, Lynx Dx announced the commercial launch of MyProstateScore 2.0 for at-home collection by patients, a test designed to accurately predict the risk of clinically significant prostate cancer using urine samples collected without a digital rectal exam.

Key Market Players

• MDx Health, Inc.
• Myriad Genetics, Inc.
• Abbott Laboratories, Inc.
• F. Hoffman-La Roche Ltd.
• Siemens Healthcare AG
• OPKO Health, Inc.
• Exact Sciences Corporation
• Regeneron Pharmaceuticals Inc.

Report Scope:

In this report, the Global Prostate Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prostate Cancer Diagnostics Market, By Test Type:

• Preliminary Tests
• Confirmatory Tests

Prostate Cancer Diagnostics Market, By Type:

• Adenocarcinoma
• Interstitial cell carcinoma
• Others

Prostate Cancer Diagnostics Market, By End use:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Prostate Cancer Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Prostate Cancer Diagnostics Market.

Available Customizations:

Global Prostate Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Prostate Cancer Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Preliminary Tests, Confirmatory Tests)
  • 5.2.2. By Type (Adenocarcinoma, Interstitial cell carcinoma, Others)
  • 5.2.3. By End use (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Prostate Cancer Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Type
  • 6.2.3. By End use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Prostate Cancer Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By End use
  • 6.3.2. Canada Prostate Cancer Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By End use
  • 6.3.3. Mexico Prostate Cancer Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By End use

7. Europe Prostate Cancer Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Type
  • 7.2.3. By End use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Prostate Cancer Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By End use
  • 7.3.2. France Prostate Cancer Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By End use
  • 7.3.3. United Kingdom Prostate Cancer Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By End use
  • 7.3.4. Italy Prostate Cancer Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By End use
  • 7.3.5. Spain Prostate Cancer Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By End use

8. Asia Pacific Prostate Cancer Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Type
  • 8.2.3. By End use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Prostate Cancer Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By End use
  • 8.3.2. India Prostate Cancer Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By End use
  • 8.3.3. Japan Prostate Cancer Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By End use
  • 8.3.4. South Korea Prostate Cancer Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By End use
  • 8.3.5. Australia Prostate Cancer Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By End use

9. Middle East & Africa Prostate Cancer Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Type
  • 9.2.3. By End use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Prostate Cancer Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By End use
  • 9.3.2. UAE Prostate Cancer Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By End use
  • 9.3.3. South Africa Prostate Cancer Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By End use

10. South America Prostate Cancer Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Type
  • 10.2.3. By End use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Prostate Cancer Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By End use
  • 10.3.2. Colombia Prostate Cancer Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By End use
  • 10.3.3. Argentina Prostate Cancer Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By End use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Prostate Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. MDx Health, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Myriad Genetics, Inc.
• 15.3. Abbott Laboratories, Inc.
• 15.4. F. Hoffman-La Roche Ltd.
• 15.5. Siemens Healthcare AG
• 15.6. OPKO Health, Inc.
• 15.7. Exact Sciences Corporation
• 15.8. Regeneron Pharmaceuticals Inc.

16. Strategic Recommendations

17. About Us & Disclaimer